Researchers Identify Two Drug Candidates for Treating Ultra-Rare XMEA Using Zebrafish Model

Researchers have identified two potential drug candidates for treating X-linked myopathy with excessive autophagy (XMEA), an ultra-rare genetic disease that progressively weakens muscles and can impact the liver and heart. The findings emerged from studies using zebrafish as a model organism to investigate the condition, which has been diagnosed in only 33 cases globally as of March 2024. The disease, inherited through the X chromosome, remains poorly understood due to its rarity.

The research focused on replicating key aspects of XMEA in zebrafish to better understand its progression and underlying mechanisms. Scientists utilized this model to screen various compounds for their therapeutic potential. Two drugs showed promise in mitigating symptoms associated with the disease during preliminary testing. While further studies are required to confirm their efficacy and safety, these findings mark a significant step forward in exploring treatment options for individuals affected by this rare disorder.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: June 5, 2025

Related posts:

International R&D Partnerships Speed Generic Drug Development, Improve Quality, and Facilitate Resource Sharing Biosimilar Efficacy Trials Face Complex Regulatory Path, FDA Framework Requires Comprehensive Similarity Assessment Novo Nordisk Implements Measures to Expand Wegovy Access Following FDA Ban on Semaglutide Compounding Practices Venus Remedies Renews GMP Certification in Ukraine for Baddi Facility Producing Antibiotics and Oncology Injectables

Author

Mark Chiang